T-lymphocyte and thymocyte surface antigens

T-lymphocyte and thymocyte surface antigens encompass a diverse array of proteins found on the surface of T-cells and their precursors, thymocytes. These antigens include critical molecules such as CD2, CD3, CD4, CD8, CD25, and CD52, which are essential for T-cell maturation, activation, and immune signaling (DrugBank, DB00033). They play a fundamental role in the adaptive immune system by facilitating cell-cell interactions and the recognition of foreign antigens. In clinical practice, this collective group of antigens serves as the target for polyclonal antibodies like Anti-thymocyte globulin (ATG), which is used to induce immunosuppression (StatPearls, NBK541065). ATG works by binding to these multiple surface markers, leading to the depletion of T-lymphocytes through complement-mediated lysis, opsonization, and apoptosis (PubMed, 21615170). This broad targeting is particularly effective in preventing and treating acute organ transplant rejection and graft-versus-host disease. However, because these antigens are central to immune function, their modulation can lead to significant side effects such as cytokine release syndrome and increased risk of infection.

Other names

T-cell surface antigensThymocyte antigensCD antigensT-lymphocyte antigensCluster of differentiation markers

Polyclonal antibodies bind to various T-cell surface antigens, leading to T-cell depletion via complement-dependent lysis, opsonization, and apoptosis, as well as modulation of T-cell function.